Lilly will withdraw the cancer drugs it purchased with AurKa

Lilly has announced a acquisition of AurKa Pharmaceuticals, bringing back indoor experimental fisrt-in-class AK-01 cancer drugs.
, AurKa is currently conducting a Phase I clinical trial of Aurora Kinase A inhibitors in a variety of types of solid tumors.
AK-01 has been shown to be highly selective for Aurora A, which is thought to play a key role in cell division by controlling chromosomal separation and is frequently overexposed in cancerous tumors.
Under the terms of the agreement, Lilly will acquire all of AurKa's shares, with an advance payment of $110 million, and up to $465 million in management and sales milestones that should be approved by AK-01 in the United States and other markets and reach a certain level of sales.
The acquisition supports Lilly's external innovation strategy, "and we seek to work with leading life sciences venture capital firms to identify, support and achieve promising innovations in areas of unsoled medical needs," said Darren Carroll, senior vice president of business development at the company. (China Pharmaceutical 123 Network)